retatrutide side effects phase 2 trial Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized 2a Retatrutide Side Effects Research |

If you want to step back and look at the wider picture, our overview of weight loss medication in the UK covers what is currently licensed and how the options compare across price, eligibility and clinical evidence

Some customers report life-changing weight loss results within weeks , while others describe months of wasted money on medications that produced zero appetite suppression and zero change on the scale

Zepbound still covered for OSA, Wegovy for cardiovascular disease [14] Blue Cross Blue Shield of Michigan: Ended all GLP-1 weight loss coverage for fully-insured large groups on 1/1/2025 [2] Blue Shield of California: Limited coverage to Class III (morbid) obesity only as of 1/1/2025 [3] BCBS of Massachusetts: Ended coverage for Wegovy, Zepbound, Saxenda starting 1/1/2026 [4] California Medi-Cal projects saving $85M in 2025-26, rising to $790M by 2028-29

However, for overall health, those who already drink should limit alcohol intake to 1-2 drinks per night

Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: Differences and similarities